България - български - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v. - Респираторно-синцитиальный вирус от едър рогат добитък (brsv), прецедете jencine-2013; видео; parainfluenza virus тип 3 говеждо месо (ПИ3), прецедете int2-2013, видео - Спрей за нос, лиофилизат и разтворител за суспензия за интраназално приложение - 5.0 – 7.0 log10 tcid50; 4.8 – 6.5 log10 tcid50 - говеда

България - български - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v - synoviae микоплазма, жив щам на МС1 - лиофилизат за суспензия - ≥ 10 на степен 6,5 и ≤ 10 на степен 8,0 cfu - пилета

Европейски съюз - български - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - рекомбинантный вирус везикулярного стоматит (щам Индиана) със заличаването на плик гликопротеин, заменени от Ебола Заир (щам киквите 1995) повърхностен гликопротеин - Хеморагична Треска Ебола - Ваксини - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. Използването на ervebo трябва да бъде в съответствие с официалните препоръки.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Европейски съюз - български - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Европейски съюз - български - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - Грип, Човек - Ваксини - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Европейски съюз - български - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - Имунни серуми и имуноглобулини - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Европейски съюз - български - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Европейски съюз - български - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Имунни серуми и имуноглобулини - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Европейски съюз - български - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - Ваксини - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 и 5. 1 in product information document). Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.